Mark Feneley has been a Consultant Urologist since 2000. He was appointed to his present position a Senior Lecturer in Urological Oncological Surgery at the Institute of Urology, University College London and Honorary Consultant Urologist at University College London Hospitals (UCLH) in 2004. This followed from a definitive Consultant Urological Oncological Surgeon position at the Middlesex Hospital and UCLH NHS Trust from January 2003, and prior to that Consultant Urologist with specialist interest in urological oncology at Nottingham City Hospital from 2000.
Mark is Clinical Lead for Bladder Cancer in the North Thames Cancer Network. He consults in specialist clinics for bladder cancer at University College London, the Royal Free and Whittington Hospitals. His specialist practice for bladder cancer includes photodynamic diagnosis of bladder cancer, and intravesical treatments for nonmuscle invasive bladder cancer. Intravesical treatments include BCG, electromotive drug administration with chemotherapy (usually mitomycin C, and a new treatment called Hyperthermia that also uses chemotherapy. Hyperthermia is being evaluated in a clinical trial for which he is the Principle Investigator at UCLH.
Clinical practice also includes diagnosis and treatment of urological cancers, as well as other important general urological conditions. He advises and guides many patients through the diagnostic investigations and treatment choices, unbiased by no longer personally carrying out radical operations. He has extensive past experience in pelvic surgery, both for bladder and prostate cancer, which have now become the remit of “robotic” surgeons, with whom he works and advises closely. For many patients, alternatives need to be considered, and take account of other medical conditions, aging and individual perspective.
Mark gained particular uro-oncological experience during a two-year Fellowship in Urological Oncology at The Johns Hopkins Hospital, Baltimore, USA. There he studied radical prostatectomy and treatment of bladder cancer with Dr Patrick Walsh. For advanced training in surgery for bladder cancer, he received a Preceptorship at The Urological Institute, Mansoura, Egypt, awarded by the British Urological Foundation.
Mark has particular training and expertise in major pelvic urological surgery, including nerve-sparing radical prostatectomy and radical cystectomy. Special interests include early detection of urological malignancy, investigation and treatment of early stage prostate cancer, action of testosterone in the prostate, bladder cancer, and kidney cancer. He also runs a general urological diagnostic and surgical practice for investigation, diagnosis and treatment of most urological conditions.
In 1998, he worked in the USA for two years, at the James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland. This was a Clinical Post-Doctoral Fellowship in Urological Oncology giving particular additional training and experience in advanced techniques in prostatic and pelvic surgery in a world-leading centre.
Mark qualified as a doctor at Cambridge University in 1987, and completed higher Urological training at St Bartholomew’s and Royal London Hospitals, London in 1998.
As Teacher and Examiner at the Royal Free and University College Medical School, responsibilities include:-
MD Supervisor; Teacher - Institute of Urology MSc Course; Teacher - Institute of Urology GP Diploma Course; Teacher - Registrar Training Scheme; Teacher - Undergraduate Lecture Course; Teacher - Undergraduate and ward based teaching; Teacher - University College London; Organiser - Undergraduate Teaching in Urology; Examiner for MD Degree, University of London; Examiner for Undergraduate Medical Examinations and OSCI, UCL; Examiner for Diploma Course, Institute of Urology, UCL; Examiner for MSc Course, Institute of Urology, UCL; Faculty of Royal College of Surgeons Anatomy Course; Faculty of Oxford Anatomy Course
Current Medical Committee Representation
We will back to you within 48 hours. Required fields are marked *
We are recognised providers by all major health insurance companies.